
Jane J. Zara
Examiner (ID: 18595)
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1674, 1637, 1635 |
| Total Applications | 1842 |
| Issued Applications | 1032 |
| Pending Applications | 285 |
| Abandoned Applications | 583 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15711597
[patent_doc_number] => 20200102564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-02
[patent_title] => Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
[patent_app_type] => utility
[patent_app_number] => 16/141464
[patent_app_country] => US
[patent_app_date] => 2018-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22664
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16141464
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/141464 | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms | Sep 24, 2018 | Abandoned |
Array
(
[id] => 16157231
[patent_doc_number] => 20200216848
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-09
[patent_title] => VARIANT RNAi
[patent_app_type] => utility
[patent_app_number] => 16/649042
[patent_app_country] => US
[patent_app_date] => 2018-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27557
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -124
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649042
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/649042 | Variant RNAi | Sep 20, 2018 | Issued |
Array
(
[id] => 14310333
[patent_doc_number] => 20190144870
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
[patent_app_type] => utility
[patent_app_number] => 16/137046
[patent_app_country] => US
[patent_app_date] => 2018-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88138
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16137046
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/137046 | Compositions and methods for inhibiting expression of the ALAS1 gene | Sep 19, 2018 | Issued |
Array
(
[id] => 15650273
[patent_doc_number] => 20200087666
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => COMPOUNDS TARGETING LONG NON CODING RNA FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/130018
[patent_app_country] => US
[patent_app_date] => 2018-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21338
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16130018
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/130018 | COMPOUNDS TARGETING LONG NON CODING RNA FOR THE TREATMENT OF CANCER | Sep 12, 2018 | Abandoned |
Array
(
[id] => 16369107
[patent_doc_number] => 10800848
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-13
[patent_title] => Nucleic acid-polypeptide compositions and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/128417
[patent_app_country] => US
[patent_app_date] => 2018-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 136
[patent_figures_cnt] => 184
[patent_no_of_words] => 96271
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16128417
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/128417 | Nucleic acid-polypeptide compositions and uses thereof | Sep 10, 2018 | Issued |
Array
(
[id] => 16336574
[patent_doc_number] => 10787519
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-29
[patent_title] => Nucleic acid-polypeptide compositions and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/128428
[patent_app_country] => US
[patent_app_date] => 2018-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 136
[patent_figures_cnt] => 184
[patent_no_of_words] => 96233
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16128428
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/128428 | Nucleic acid-polypeptide compositions and uses thereof | Sep 10, 2018 | Issued |
Array
(
[id] => 18428929
[patent_doc_number] => 11674140
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-13
[patent_title] => Compositions and methods for treating facioscapulohumeral dystrophy
[patent_app_type] => utility
[patent_app_number] => 16/643772
[patent_app_country] => US
[patent_app_date] => 2018-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 54
[patent_no_of_words] => 12536
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643772
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/643772 | Compositions and methods for treating facioscapulohumeral dystrophy | Sep 6, 2018 | Issued |
Array
(
[id] => 14159187
[patent_doc_number] => 20190106696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-11
[patent_title] => CHIRAL DESIGN
[patent_app_type] => utility
[patent_app_number] => 16/109638
[patent_app_country] => US
[patent_app_date] => 2018-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 106071
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16109638
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/109638 | Chiral design | Aug 21, 2018 | Issued |
Array
(
[id] => 16476495
[patent_doc_number] => 10851424
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-01
[patent_title] => MicroRNA profiling for diagnosis of dysplastic nevi and melanoma
[patent_app_type] => utility
[patent_app_number] => 15/999033
[patent_app_country] => US
[patent_app_date] => 2018-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 20587
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15999033
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/999033 | MicroRNA profiling for diagnosis of dysplastic nevi and melanoma | Aug 19, 2018 | Issued |
Array
(
[id] => 18102350
[patent_doc_number] => 11542225
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Lipids for use in lipid nanoparticle formulations
[patent_app_type] => utility
[patent_app_number] => 16/638728
[patent_app_country] => US
[patent_app_date] => 2018-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18983
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 221
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638728
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/638728 | Lipids for use in lipid nanoparticle formulations | Aug 16, 2018 | Issued |
Array
(
[id] => 16792886
[patent_doc_number] => 20210122703
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 16/638731
[patent_app_country] => US
[patent_app_date] => 2018-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16834
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638731
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/638731 | Lipids for use in lipid nanoparticle formulations | Aug 16, 2018 | Issued |
Array
(
[id] => 19075333
[patent_doc_number] => 11944676
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-02
[patent_title] => Systems and methods for the control of acute hepatopancreatic necrosis disease
[patent_app_type] => utility
[patent_app_number] => 16/637612
[patent_app_country] => US
[patent_app_date] => 2018-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 20703
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637612
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/637612 | Systems and methods for the control of acute hepatopancreatic necrosis disease | Aug 6, 2018 | Issued |
Array
(
[id] => 16466636
[patent_doc_number] => 20200368173
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE
[patent_app_type] => utility
[patent_app_number] => 16/636177
[patent_app_country] => US
[patent_app_date] => 2018-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 80059
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636177
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/636177 | Nucleic acid-containing lipid nanoparticle | Aug 5, 2018 | Issued |
Array
(
[id] => 16843120
[patent_doc_number] => 11015194
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-25
[patent_title] => iRNA agents with biocleavable tethers
[patent_app_type] => utility
[patent_app_number] => 16/042633
[patent_app_country] => US
[patent_app_date] => 2018-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 19
[patent_no_of_words] => 54175
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16042633
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/042633 | iRNA agents with biocleavable tethers | Jul 22, 2018 | Issued |
Array
(
[id] => 17620331
[patent_doc_number] => 11339370
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-24
[patent_title] => Cell line with METTL3 gene knocked out, its construction method and interference vector
[patent_app_type] => utility
[patent_app_number] => 17/417764
[patent_app_country] => US
[patent_app_date] => 2018-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 8
[patent_no_of_words] => 2204
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 157
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417764
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/417764 | Cell line with METTL3 gene knocked out, its construction method and interference vector | Jul 20, 2018 | Issued |
Array
(
[id] => 16703191
[patent_doc_number] => 10953105
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-23
[patent_title] => Immunostimulatory compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/040181
[patent_app_country] => US
[patent_app_date] => 2018-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 47
[patent_no_of_words] => 20296
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16040181
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/040181 | Immunostimulatory compositions and methods of use thereof | Jul 18, 2018 | Issued |
Array
(
[id] => 14342941
[patent_doc_number] => 20190153443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-23
[patent_title] => METHODS FOR INCREASING EFFICACY OF LIPID FORMULATED siRNA
[patent_app_type] => utility
[patent_app_number] => 16/036550
[patent_app_country] => US
[patent_app_date] => 2018-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45431
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16036550
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/036550 | METHODS FOR INCREASING EFFICACY OF LIPID FORMULATED siRNA | Jul 15, 2018 | Abandoned |
Array
(
[id] => 13826581
[patent_doc_number] => 20190016775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => Immunogenic Compositions
[patent_app_type] => utility
[patent_app_number] => 16/029878
[patent_app_country] => US
[patent_app_date] => 2018-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029878
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/029878 | Immunogenic Compositions | Jul 8, 2018 | Abandoned |
Array
(
[id] => 16175476
[patent_doc_number] => 20200222444
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => METHODS OF INHIBITING CELL PROLIFERATION AND METTL8 ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 16/628597
[patent_app_country] => US
[patent_app_date] => 2018-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628597
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/628597 | Methods of inhibiting cell proliferation and METTL8 activity | Jul 5, 2018 | Issued |
Array
(
[id] => 16533533
[patent_doc_number] => 10876118
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-29
[patent_title] => Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
[patent_app_type] => utility
[patent_app_number] => 16/028262
[patent_app_country] => US
[patent_app_date] => 2018-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 32
[patent_no_of_words] => 21301
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16028262
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/028262 | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell | Jul 4, 2018 | Issued |